(). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Radiobiological. Kim, & Blakeney, ). Experiences of case managers in providing. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. , & Reijneveld, S. Radiother. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, van Tinteren H, Praag JO, et al. ; (2), KIM MS et al. Quality of life. Planning of radiotherapy capacity and productivity. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kumar,. . SLOTMAN B, SENAN S.